BayMedica

12/28/2023

Dr. Shane Johnson at InMed Pharmaceuticals subsidiary BayMedica speaks with Benzinga about "Turning Sugars Into Pure, Pharma-Grade Rare : This Company's Breakthrough"

https://ow.ly/nmCp50QmpKL

$INM

In an exclusive interview with Benzinga, Dr. Shane Johnson, MD, senior vice president and general manager of BayMedica, sheds light on the company's innovative approach to cannabinoid production.

11/28/2023

Come visit us at this week! Ask us about our rare . We're at booth 7638!

10/11/2023

BayMedica’s VP of Sales and Marketing, Jerry Griffin, joins this live panel discussion at the Benzinga Cannabis Capital Conference to talk about the growing industry and how CPG companies are creating valuable innovative products with ingredients.

Watch panel discussion: https://ow.ly/HmT050PVjwT

$INM

10/10/2023

Dr Shane Johnson joins Water Tower Hour host Jesse Redmond to talk about and their market opportunity, the importance of consistency for CPG products and the challenges of the current landscape.

Listen here: https://www.inmedpharma.com/media-news/water-tower-hour-shane-johnson/

$INM

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, is a guest on The Water Tower Hour. Host Jesse Redmond, Senior Analyst at Water Tower Research interviewed Shane live at the Benzinga Cannabis Capital Conference in Chicago September 28th. In this interview, Shane talks about InMed and BayMed...

05/06/2022

is one of the most researched . CBDV has been researched for its physiological effects and has been the subject of many studies for its therapeutic potential. Learn more here: https://www.baymedica.com/2022/04/23/5-things-to-know-about-cbdv/

05/05/2022

News: InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of

“As a company driven by data and science, independent third-party research provides important information as we continue to expand our product portfolio of rare cannabinoids for the health and wellness market. Evidence-based decision making is key to facilitate adoption of rare cannabinoids by consumers, brands and healthcare providers. This research will advance the understanding of rare cannabinoids, which have been historically under-investigated.” Dr. Shane Johnson, SVP and General Manager of BayMedica.

News release: http://ow.ly/NgES50IZP9U

$INM

05/05/2022

News: InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of

“We are excited to be part of this groundbreaking study with Trokie and Radicle Science in advance of our commercial launch of d-9 dominant THCV. Radicle Science has been at the forefront of cannabinoid research, providing much needed scientific evidence to validate the effects of cannabinoids, and Trokie is a leader in unique and effective delivery systems for cannabinoids.” Dr. Shane Johnson, SVP and General Manager of BayMedica.

News release: http://ow.ly/wm2050IZP3q

$INM

05/05/2022

NEWS: InMed is pleased to announce that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science's Radicle Energy study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin on energy, focus/attention, appetite and weight/BMI. BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie.

Full news release here: http://ow.ly/p2GR50IZOON

$INM

04/29/2022

Through our novel synthetic methods, we manufacture and custom formulations for a variety of consumer applications including supplements, , , and more.

Check out our latest news here: https://investors.inmedpharma.com/news-releases/news-release-details/inmed-commercializes-cannabidivarin-cbdv-expanding-its-rare

04/22/2022

What is ? 5 Things to Know about CBDV.

We have commenced B2B sales of CBDV. Learn more about this rare and sign up to get a copy of our CBDV White Paper: https://www.baymedica.com/cannabidivarin-cbdv/

04/21/2022

BayMedica launches B2B sales of

“We are excited to continue to introduce to the market additional rare cannabinoids that have previously not been abundantly accessible, including adding THCV to our portfolio in the immediate future."

News: http://ow.ly/L30Q50IOP9T
About CBDV: http://ow.ly/yRei50IOP9S

$INM